More on UNCY

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+23.9% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (11/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Unicycive Therapeutics, Inc (NQ:UNCY)
Delayed: 3.36 -0.23 (6.41%)
Prev. Close $3.59  
Open$3.58 
52 Wk High$ 
52 Wk Low$ 
Day High$3.60 
Day Low$3.35 
P/E N/A  
EPS$ 
Volume1,102,275 

Friends, Peers and Foes (?): FIVE, HUM, MOH, SLNO, APLT (more...)

Oct 1, 2026 04:30 PM Form 3 Unicycive Therapeutics, For: Oct 01 Filed by: Manning Meredith
Oct 1, 2026 07:05 AM Unicycive Therapeutics adds Meredith Manning to its board
Oct 1, 2026 07:05 AM Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Sep 29, 2026 03:22 PM UNCY LAWSUIT: Unicycive Therapeutics Investors Should Contact Block & Leviton to Possibly Recover Losses
Sep 29, 2026 07:47 AM Form 8-K Unicycive Therapeutics, For: Sep 28
Sep 29, 2026 07:05 AM Unicycive resubmits NDA for kidney disease drug with new manufacturer
Sep 29, 2026 07:05 AM Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Sep 28, 2026 04:31 PM Form 8-K Unicycive Therapeutics, For: Sep 03
Aug 20, 2026 09:10 AM Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
Aug 14, 2026 04:46 PM Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: Nantahala Capital Management, LLC
View All Articles

Entities mentioned with UNCY

View All Entities